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Background:Matrix metalloproteinase-9 (MMP-9) is thought to play a central role in abdominal aortic aneurysm (AAA)
initiation. Doxycycline, a tetracycline analogue, has direct MMP-9-inhibiting properties in vitro, and it effectively
suppresses AAA development in rodents. Observed inhibition of AAA progression, and contradictory findings in human
studies evaluating the effect of doxycycline therapy on aortic wall MMP-9, suggest that the effects of doxycycline extend
beyond MMP-9 inhibition and that the effect may be dose-dependent.
Methods: This clinical trial evaluated the effect of 2 weeks of low- (50 mg/d), medium- (100 mg/d), or high-dose (300
mg/d) doxycycline vs no medication in four groups of 15 patients undergoing elective AAA repair. The effect of
doxycycline treatment on MMP and cysteine proteases, and their respective inhibitors, was evaluated by quantitative
polymerase chain reaction, Western blot analysis, immunocapture protease activity assays, and immunohistochemistry.
Results: Doxycycline was well tolerated and no participants dropped out. Doxycycline treatment reduced aortic wall
MMP-3 and MMP-25 messenger RNA expression (P < .045 and P < .014, respectively), selectively suppressed
neutrophil collagenase and gelatinase (MMP-8 and MMP-9) protein levels (P < .013 and <.004, respectively), and
increased protein levels of the protease inhibitors tissue inhibitor of metalloproteinase 1 and cystatin C (P< .029). As for
the apparent selective effect on neutrophil-associated proteases, we sought for a reducing effect on aortic wall neutrophil
content that was indeed confirmed by immunohistochemical analysis that revealed a 75% reduction in aneurysm wall
neutrophil content (P < .001).
Conclusions: Independent of its dose, short-term preoperative doxycycline therapy improves the proteolytic balance in
AAA, presumably through an effect on aortic wall neutrophil content. This study provides a rationale for doxycycline
treatment in patients with an AAA as well as in other (vascular) conditions involving neutrophil influx such as Kawasaki
disease and Behçet disease. ( J Vasc Surg 2009;49:741-9.)
Clinical Relevance: The concept of pharmaceutical stabilization of abdominal aneurysms is promising. Doxycycline, a
tetracycline analogue, is considered a lead candidate, but its mode of action is still unclear. This clinical trial showed that
doxycycline treatment, through a profound effect on the number aortic wall neutrophils, has a pronounced but selective
effect on the proteolytic balance in the abdominal aneurysm, as indicated by reduced matrix metalloproteinase (MMP)-8
and -9 levels and concentrations of tissue inhibitor of metalloproteinase-1 and cystatin C. The observation that
doxycycline has a selective effect on neutrophil-derived proteases is remarkable and novel, and suggests that doxycycline
may also be effective in other vascular conditions involving neutrophils, such as Kawasaki disease and Behçet disease, and
nonvascular conditions such as chronic obstructive pulmonary disease.An aneurysm of the abdominal aorta (AAA) is a com-
mon pathology and a major cause of death due to rupture.1
Risk of rupture is negligible in small AAAs, but increases
exponentially in AAAs with a diameter of 55 mm.1
Hence, current approaches toward AAAs are surveillance of
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doi:10.1016/j.jvs.2008.09.055small AAAs and preventive surgical repair of larger AAAs
(ie, 55 mm).2 Unfortunately, conventional transabdom-
inal (open) repair is associated with considerable morbidity
and mortality.3 Although short-term results of endovascu-
lar repair appear more favorable, rates of mid- and long-
termmortality are similar to those of conventional repair.4,5
Endovascular repair, moreover, requires life-long follow-
up, and the number of reinterventions after endovascular
repair is high (approximately 9%), although most are mi-
nor.6 As a consequence, the effectiveness of endovascular
AAA repair is now being challenged.7,8
Pharmaceutical therapy inhibiting aneurysmal growth,
and thus reducing the need for invasive treatment, could
have major advantages for patients as well as socioeconomic
benefits.9 Excess matrix degradation that is not balanced
by matrix deposition is considered pivotal to aneurysmal
growth.1 This led to the proposal that pharmaceutical
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ular, matrix metalloproteinase-9 (MMP-9), could restore
the balance between matrix degradation and deposition
and thus reduce aneurysmal growth.10,11
Members of the tetracycline family of antibiotics have
been recognized as inhibitors of MMP expression and
activity. It was thus proposed that doxycycline, a tetracy-
cline analogue, may reduce excess MMP-9 activity in AAA
and constitute a pharmaceutical means of reducing aneu-
rysmal growth.10,11 Indeed, doxycycline has been shown to
inhibit aneurysm formation in various animal models of
AAA.10-13 Moreover, results from two preliminary phase
I/II studies in patients under surveillance for AAA suggest
that long-term doxycycline treatment may also attenuate or
even forestall aneurysm growth.14,15
Despite these promising findings, a number of ques-
tions, in particular themode of action of the drug,16 remain
to be answered. The rationale behind doxycycline therapy
was to prevent aneurysmal growth through inhibition of
elastolysis mediated by MMP-9.10,17 Yet, it is now recog-
nized that loss of elastin is a very early event in AAA
formation and that aneurysmal growth and ultimate rup-
ture essentially depend on loss of structural collagens.1,18
However, MMP-9 is a gelatinase that can only degrade
collagen after initial cleavage by specific collagenases.18
Observed inhibition of aneurysmal growth in animal mod-
els and human studies therefore suggests that apart from its
effects on MMP-9, doxycycline therapy also influences the
collagenases.
A recent study19 evaluated the effect of preoperative
doxycycline treatment on messenger RNA (mRNA) ex-
pression of the collagenasesMMP-1,MMP-13, andMMP-
14, but failed to observe an effect on these proteases. The
effects on the primary collagenases in AAA (MMP-8 and
the cysteine proteases cathepsins K, L, or S)18 were not
evaluated.
Another issue that has not been addressed is the con-
tradictory results of human studies evaluating the effects of
doxycycline on MMP-9 expression and activity. Although
the initial human study showed that preoperative doxycy-
cline reduced MMP-9 mRNA expression and activity,17 a
later more elaborate study failed to observe such an effect.19
The basis for these divergent findings is unclear, but they
may reflect increased MMP-9 expression as result of an
immunostimulatory effect on monocytes as seen at higher
doses of tetracyclines20; indicating that the contrasting
findings in human studies may reflect a dose–response
relationship.
To evaluate the effects of doxycycline therapy on the
MMP and cysteine proteases,18 their respective inhibi-
tors,18,21 and to test whether the apparent contradic-
tory findings of human studies on MMP-9 relate to dose-
dependency, we evaluated the effect of low (50 mg/d)
regular (100 mg/d) and high (300 mg/d) doses of doxy-
cycline on the members of the MMP family of proteases
and the cysteine collagenases cathepsin K, L, and S. Results
from this study show that, irrespective of dose, 2 weeks
of preoperative doxycycline treatment improves the pro-teolytic balance through reduction of the neutrophil-
associated proteases MMP-8, MMP-9 and MMP-25, and
an increase of the protease inhibitors tissue inhibitor of
metalloproteinase 1 (TIMP1) and cystatin C. Further eval-
uation of this phenomenon showed that doxycycline ther-
apy profoundly reduced the number of infiltrating neutro-
phils in the aneurysmal wall.
METHODS
Patients. The study was performed on intention-to-
treat basis. The study included 60 patients scheduled for
elective, open aneurysm repair and excluded patients with
chronic inflammatory disease or inflammatory aortic aneu-
rysms. Decisions for open repair were based on anatomic
(eg, neck, elongation) and patient characteristics (age), and
on patient preferences. Patients were randomly assigned to
receive 50, 100 or 300 mg doxycycline per day, or no
medication (control group), with 15 patients in each
group. In two patients in the low-dose doxycycline group,
the operation had to be postponed because of full occu-
pancy of the intensive care unit; therefore, 13 patients were
evaluated in this group. Medication was started 14 days
before the planned operation, and the last dose was taken in
the evening before surgery. Postoperative outcome was
similar in all groups.
Procedure. The aneurysm sac was opened and adher-
ing thrombus was manually removed. A tissue sample was
obtained from the anterior-lateral aneurysm wall at the
maximum diameter of the aneurysm. Wall samples were
immediately halved. One half was snap-frozen in carbon
dioxide-cooled isopentane or liquid nitrogen and stored at
80°C for later analysis. The other half was fixed in form-
aldehyde (24 hours), decalcified (Kristensens solution, 120
hours), and paraffin-embedded for histologic analysis. All
analyses were performed in a researcher-blind fashion.
For comparison of AAA wall with nonaneurysmal wall,
we used nonaneurysmal aortic wall samples from brain-
dead kidney donors. Only patches displaying advanced
atherosclerotic lesions (equalling the characteristics of
grade IV-VI lesions by the Stary classification)22 were se-
lected. The nonaneurysmal control group comprised 11
patients (7 men, 4 women) aged 55.6 10.2 years, with an
aortic diameter of 2.0-cm. All nonaneurysmal control
samples were obtained from the level of the renal artery and
during a laparotomy (ie, from a comparable region and
during a similar procedure as the AAA samples).
The study was approved by the Medical Ethical Com-
mittee of the Leiden University Medical Centre (LUMC),
Leiden, The Netherlands.
RNA isolation and real-time quantitative poly-
merase chain reaction. RNA isolation and quantitative
mRNA analysis by LightCycler Real-time polymerase
chain reaction (PCR, Applied Biosystems, Nieuwerkerk
aan den Ijssel, The Netherlands) were performed by
following previously published protocols.21 All mRNA
data were standardized on basis of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression.
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verized in liquid nitrogen and homogenized in lysis buffer
(10mM Tris, pH 7.0; 0.1mM calcium chloride, 0.1M
sodium chloride, 0.25% (v/v) Triton X-100). This proto-
col releases both soluble as well as membrane-bound pro-
teases. Samples were subsequently centrifuged at 13,000
rpm for 10 minutes at 4°C, snap-frozen, and stored at
–80°C until use. Homogenates were standardized accord-
ing to their protein content (Pierce, Rockford, Ill).
Specific immunocapture MMP activity assays.
MMP-1, MMP-2, MMP-8, MMP-9, MMP-13, and
MMP-14 activity assays (Amersham Biosciences, Bucking-
hamshire, United Kingdom [UK]) were performed accord-
ing to the supplier’s recommendations. In these assays,
target proteases are captured by a specific antibody immo-
bilized on microtiter plates, and the proteolytic activation
of a modified proenzyme by the captured protease is used
to quantify the activity of the captured protease. These
assays allow sensitive and specific assessment of active
MMPs, as well as pro-MMP upon activation of latentMMP
by a mercuric salt (p-aminophenylmercuric acetate) in in
vitro systems.
Western blot analysis. Western blot analysis was used
to quantify the amount of proenzyme as well as the prece-
ding protease activation through quantification of the
amount of activated protease that was present in the tissue
homogenates as protease-inhibitor complex.18 Preliminary
analyses showed that the antibodies used allow evaluation
of both pro and active forms of the respective proteases and
that the standard denaturing conditions required for West-
ern blot analysis result in full dissociation of MMP–TIMP
and cathepsin–cystatin C complexes, thus showing that
these analyses allow assessment of inhibitor-bound MMPs
and cathepsins.18
Western blot analyses for the proteases, as well as for
cystatin C and TIMP1, were performed as previously de-
scribed23 using the antibodies antihuman MMP-2 (PC-
158, the Bindingsite, Birmingham, UK), anti-MMP-3
(PC-112, the Bindingsite), anti-MMP-7 (RP1MMP7,
Triple Point Biologics, Cambridge, UK), anti-MMP8
(MAB3316, Chemicon, Chemicon Europe Ltd, Chandlers
Ford,UK), anti-MMP-9 (TNO-BEA-21, TNO, Leiden, The
Netherlands), anti-cathepsin K (IM55L, Calbiochem, Breda,
The Netherlands), anti-cathepsin L (AF952, R&D Systems,
Abingdon, UK), anti-cathepsin S (sc-6505, Santa Cruz,
Heerhugowaard, The Netherlands), anti-cystatin C (sc-
16989, Santa Cruz), and anti-TIMP1 (AB8229, Chemi-
con). The amount of protein in all samples was standard-
ized using actin levels (anti-actin sc-1615, Santa Cruz).
All secondary antibodies were obtained from Santa
Cruz Biotechnology (Heerhugowaard, The Netherlands).
Immunoblots were visualized using Super Signal West Dura
Extended Duration Substrate (Perbio Science, Etten-Leur,
The Netherlands), and a luminescent image workstation
(UVP, Cambridge, UK). LabWorks 4.6 software (UVP, Up-
land, Calif) was used to quantify the immunoblots.
Immunohistochemistry. Immunohistochemistry was
performed using 4-m deparaffinized, ethanol-dehydratedtissue sections. Sections were incubated overnight with a
myeloperoxidase (A 0398 DAKO, Heverlee, Belgium), a
MMP-8 (Medix Biochemica, Milsbeek, The Netherlands),
or a CD68 (M 0718 DAKO) antibody. Sections were
stained with Nova Red (Vector Laboratories, Burlingame,
Calif) and counterstained with Mayer hematoxylin. Con-
trols were performed by omitting the primary antibody.
Specificity of myeloperoxidase staining for neutrophils was
validated by morphometric analysis of myeloperoxidase-
positive cells by an experienced vascular pathologist (Dr
J. H. von der Thüsen). Slides were examined by two
independent observers who were unaware of the patient’s
status.
Statistical analysis. Expression of mRNA was com-
pared by t test or Wilcoxon Mann-Whitney U test, where
appropriate. Results of the Western blots and immunohis-
tochemistry were analyzed by Wilcoxon- Mann-WhitneyU
test to compare different groups. Statistical significance was
accepted at a value of P  .05. Many findings in this study
reflect correlated data, and as such a Bonferroni correction
was not applied for the data in this study. Yet, a Bonferroni
correction should be considered when interpreting the
results of uncorrelated data. Possible dose–response rela-
tionships were evaluated by quadratic regression analysis.
All analyses were performed using SPSS 12.0.1 software
(SPSS Inc, Chicago, Ill).
RESULTS
Patients. Clinical characteristics of the patients are
compiled in the Table. All four groups were comparable
with regard to age, sex, pharmaceutical treatment, and
AAA diameter. Owing to the reticence toward statin use in
The Netherlands, 10% of the patients in the study were
receiving statin therapy. Doxycycline treatment was well
tolerated, and no patients dropped out.
Effects of doxycycline treatment on MMP expres-
sion and activation. Compared with nonaneurysmal con-
trol aorta wall, AAA tissue was characterized by increased
mRNA expression of soluble MMP-3 (P  .029) and
MMP-9 (P  .001), as well as by abundant expression of
the membrane type MMPs, MMP-16 (P  .016) and
MMP-25 (P .001). Expression of all other proteases and
their inhibitors was similar in control tissue and AAA (Sup-
plementary Table I, online only).
Fig 1 shows that independent of its dose, 14 days of
preoperative doxycycline therapy attenuated MMP-3 (P 
.045) and MMP-25 (P .014) mRNA expression. All three
doses of doxycycline increased MMP-8 mRNA expression to
values comparable to those found in control aorta (Supple-
mentary Table II, online only). Expression of all otherMMPs,
including MMP-9, was not influenced by doxycycline treat-
ment (Supplementary Table II, online only).
Possible effects of doxycycline treatment on the post-
transcriptional regulation of MMP protein levels and activ-
ity were evaluated by specific protease activity assays and
Western blot analyses. Direct measurement of activeMMPs
in aortic tissue is not feasible because of the rapid inactiva-
tion of the active enzymes by the endogenous inhibitors18;
. *P 
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were only measured after in vitro activation of latent proen-
zymes. Results from these assays showed a maximum level
of suppression of MMP-2, MMP-8, and MMP-9 proen-
zyme levels in the low-dose doxycycline group (MMP-2,
P  .015; MMP-8, P  .013; and MMP-9, P  .004;
Fig 2). Results for the higher doses were more variable and
showed reduced aortic wall MMP-8 proenzyme levels in
the standard-dose (100 mg), and reduced MMP-9 proen-
zyme levels in the high-dose (300 mg) doxycycline group
(P .020; Fig 2). MMP-1 and MMP-13 proenzyme levels
both remained below the detection limit of the protease
activity assays.
We performed Western blot analysis to evaluate a pos-
sible effect of doxycycline treatment on protease activation.
Fig 3 shows that doxycycline treatment was associated with
a dose-independent reduction of MMP-8 and MMP-9
Table. Patient characteristics
Variablesa Control A
Evaluable patients, No. 15
Age, mean (range) y 74.8 (69
AAA diameter, mean cm 6.7
Time between diagnosis and surgery, mean mon 6
Female sex, No. 1
Current smoker, No. 6
Medication use, No.
Statin(s) 1
Antihypertensive(s) 8
Antiplatelet therapy 10
AAA, Abdominal aortic aneurysm.
aValues of P for all variables were not significant.
Fig 1. Left, Matrix metalloproteinase (MMP)-3 and (r
phosphate dehydrogenase (GAPDH). Independent of it
messenger RNA expression. Maximum level of suppres
Results for the higher doses are more variable. Results a
line), interquartile range (box borders), and range (bars)activation (P  .004). Findings for MMP-8 proenzymeparalleled results of the protease activity assays and showed
reduced MMP-8 proenzyme levels for all doses of doxycy-
cline (P  .010). However, results for MMP-9 proenz-
yme were not statistically significant in the low-dose
and normal-dose doxycycline groups (P  .073; Fig 3).
MMP-2, MMP-3, and MMP-7 proenzyme and active en-
zyme levels were not influenced by doxycycline treatment
(Supplementary Table III, online only). This indicates that
doxycycline treatment neither influenced protein levels nor
activation of these proteases.
Doxycycline treatment: cysteine protease expres-
sion and activation. Doxycycline treatment for 14 days
did not influence mRNA expression of the cysteine pro-
teases cathepsin K, L, and S (Supplementary Table II,
online only). Western blot analysis for pro and activated
forms of cathepsin K, L, and S showed that doxycycline
therapy did not influence cysteine proenzyme levels or their
Doxycycline
50 mg 100 mg 300 mg
13 15 15
72.7 (62-85) 74.1 (50-88) 72.1 (58-87)
6.5 6.3 6.7
7 5 4
2 2 3
6 7 5
1 1 2
7 8 7
8 8 8
MMP-25 transcript levels relative to glyceraldehyde-3-
, doxycycline reduces aortic wall MMP-3 and MMP-25
was already found in the low-dose doxycycline group.
sented in box plots depicting median value (horizontal
.045 and P  .014 respectively (t test).AA
-84)ight)
s dose
sion
re preactivation (Supplementary Table III, online only).
.020
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sion. With the exception of a moderate reduction of
TIMP2 mRNA expression (P  .004), none of the doxy-
cycline doses influenced expression of the protease inhibi-
tors (Supplementary Table II, online only). Yet, as shown
in Fig 4, doxycycline therapy increased cystatin C and
TIMP1 protein levels (TIMP1 normal-dose and high-dose
doxycycline only, P  .029).
Doxycycline treatment reduces neutrophil influx in
the aneurysmal wall. The rather selective reduction of
MMP-8 and MMP-9 (neutrophil collagenase and gelati-
nase, respectively) protein levels—but not of their mRNA
expression—along with reduced mRNA expression of
MT6-MMP, the neutrophil-specificMMP-25,24 suggested
that the observed effects of preoperative doxycycline treat-
ment on MMP expression are indirect and may relate to a
reduced aortic wall neutrophil content. We quantified the
aortic wall neutrophil content by immunohistochemistry
Fig 2. The effect of doxycycline on (left)matrix metallo
proenzyme levels in untreated abdominal aortic aneurysm
protease activity assays. Maximum level of suppression wa
the higher doses are more variable. *P  .015 for MM
Wilcoxon-Mann-Whitney U test. Results are presented in
range (box borders), and range (bars).
Fig 3. The effect of doxycycline on pro (gray bars)
(MMP)-8 and (right) MMP-9 levels (relative protein
aneurysm controls (n 5) and doxycycline-treated patien
are presented with the standard error (range bars). *P (myeloperoxidase staining, Fig 5) that indeed showed that2 weeks of preoperative doxycycline treatment resulted in a
profound reduction of the neutrophil content (Fig 5, P 
.001). Specificity of myeloperoxidase (Fig 5, B and C)
staining for neutrophils was validated by morphometric
analysis of myeloperoxidase-positive cells and absence of an
effect of doxycycline on myeloperoxidase mRNA expres-
sion and on aortic wall macrophage content (Supplemen-
tary Fig, online only). The findings for myeloperoxidase
staining were validated by MMP-8 staining, which showed
similar results as the myeloperoxidase staining (data not
shown).
DISCUSSION
Doxycycline has been shown convincingly to prevent
AAA formation in a variety of animal models,10-13 and the
results from two small clinical studies suggest that doxycy-
cline may also reduce AAA expansion in people.14,15 Re-
markably, although the rationale behind doxycycline ther-
inase (MMP)-2, (center)MMP-8, and (right)MMP-9
trols and doxycycline-treated patients as measured in the
ady found in the low-dose doxycycline group. Results for
P  .013 for MMP-8, and P  .004 for MMP-9 by
lots depicting median value (horizontal line), interquartile
activated (white bars) (left) matrix metalloproteinase
, mean control, 100%) in untreated abdominal aortic
 4 per dose) measured byWestern blot analysis. Results
by Wilcoxon-Mann-Whitney U test.prote
con
s alre
P-2,
box pand
levels
ts (napy is based on its putative effects on MMP-9 expression
test.
ls. Ba
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human aneurysm are unclear, with published studies17,19
suggesting that doxycycline acts through a different mech-
anism.16
In this prospective clinical trial, we examined the
effect of three pharmacologically relevant doses of
doxycycline—low (50 mg/d), regular (100 mg/d) or
high (300 mg/d)—on inflammatory processes in the
aneurysmal wall of patients scheduled for elective, open
AAA repair in an integrative approach. We first estab-
Fig 4. Doxycycline treatment increases protein levels
cysteine proteases, as well as (right) tissue inhibitor of m
only). Results are presented in box plots depicting median
range (bars). *P  .029 by Wilcoxon-Mann-Whitney U
Fig 5. A,Doxycycline reduces neutrophil content in the
median value (horizontal line), interquartile range (box
Whitney U test. B, Aneurysm wall neutrophil infiltration
zone in untreated and (C) doxycycline-treated individualished mRNA expression profiles of the MMP and cys-teine collagenases by quantitative real-time PCR. Be-
cause this approach does not provide information on the
post-transcriptional regulation of protease activity, we
applied specific protease activity assays and Western blot
analyses to address the post-translational regulation of
protease activity, and quantified tissue expression of
specific inhibitors of proteases.
Preoperative doxycycline treatment resulted in a selec-
tive reduction of MMP-8 and MMP-9 protein levels, as
well as suppression of MMP-25 mRNA expression. The
eft) cystatin C, the principle extracellular inhibitor of
oproteinase 1 (TIMP1) protein levels (100 and 300 mg
e (horizontal line), interquartile range (box borders), and
rysmal wall. Results are presented in box plots depicting
ers), and range (bars). *P  .001 by Wilcoxon-Mann-
eloperoxidase staining) in the medial-adventitial border
r represents 100 m.of (l
etall
valuaneu
bord
(myeffect on MMP-8 and MMP-9 protein levels, but not on
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MMP-25 mRNA expression,24 suggests that the effect of
doxycycline on protease expression was indirect and may
relate to suppression of neutrophil influx. Neutrophil
MMP-8 and MMP-9 are both stored (secondary granule)
proteins that are temporarily expressed during the late
myeloid maturation pathway of neutrophils and are mini-
mally expressed in mature neutrophils.25,26 This could well
account for the apparent discrepancy between the effects of
doxycycline therapy on MMP-8 and MMP-9 protein and
mRNA expression.
We evaluated a possible effect on neutrophil influx in
the aneurysm wall by immunohistochemical staining for
myeloperoxidase, the preferred neutrophil marker (Prof D.
Roos, Sanquin Research, Amsterdam, The Netherlands,
personal, communication) and indeed found that doxy-
cycline treatment profoundly reduced the number of
myeloperoxidase-positive cells. The specificity of the my-
eloperoxidase staining for neutrophils was confirmed by
morphometric analysis that showed that all myeloperoxidase-
positive cells exhibit a lobed nucleus, typical for neutro-
phils, and by MMP-8 staining that showed analogous re-
sults to the myeloperoxidase staining.
Our immunohistochemical analysis did not indicate
myeloperoxidase expression in monocytes and or macro-
phages.27 To exclude possible interference by an effect of
doxycycline on monocyte/macrophage content or their
myeloperoxidase expression, we quantified the number of
CD68-positive cells and assessed myeloperoxidase mRNA
expression, both of which remained unaffected by doxycy-
cline therapy (Supplementary data, online only).
Our observations are remarkable and suggest that
doxycycline may act through an effect on neutrophil infil-
tration. Neutrophil abundance (presumably resulting from
interleukin-8 hyperexpression) is a striking characteristic of
AAA disease,28 and neutrophils may be critically involved
in aneurysm formation and growth. Eliason et al29 and
Pagano et al30 recently showed that abrogated neutrophil
influx forestalls aneurysm formation in the elastase model
of aneurysm formation, indicating that neutrophil influx is
critically involved in aneurysm formation in this established
model of aneurysm formation. The pathophysiologic role
of the neutrophils in AAA formation and aneurysmal
growth is still unclear. Eliason et al29 showed that the effect
occurred independently from MMP-8. Our findings of
increased TIMP1 and cystatin C protein levels upon doxy-
cycline therapy provide an alternative explanation: we pre-
viously showed that cystatin C deficiency in AAA is secondary
and relates to proteolytic degradation by neutrophil-
derived proteases.18 An analogous mechanism has been
described for TIMP1,31 suggesting that neutrophils may
unfavorably influence the proteolytic balance through an
effect on the inhibitors of protease activity.
Doxycycline has been shown to inhibit neutrophil mi-
gration in in vitro studies and studies in healthy volun-
teers32; but to our knowledge, this is the first clinical study
showing that doxycycline treatment results in a significantly
reduced neutrophil influx in a chronic inflammatory condi-tion such as AAA. The mechanism underlying the reduced
neutrophil influx is yet unclear. Tetracyclines, including
doxycycline, are known for their pleiotropic immuno-
modulatory activities that include suppression of inducible
nitric oxide synthase and cyclooxygenase-2 expression.33
Both pathways are implicated in the perpetuation of the
inflammatory processes of AAA,34,35 suggesting that doxy-
cycline treatment may act by attenuation of vascular in-
flammation. Sugita et al,36 on the other hand, showed
that doxycycline treatment by chelation of intracellular
Ca-ions resulted in a dose-dependent inhibition of neu-
trophil chemotaxis. Reductions in aortic wall neutrophil
content in patients in this study occurred independently of
the dose and were already maximal at the sub-antimicrobial
dose of doxycycline, suggesting that the effect relates to an
anti-inflammatory mechanism.
Independent of its effects on neutrophil influx, doxy-
cycline may further act through direct inhibition of MMP
activity (zinc scavenging).37 Presumably, this effect is dose-
dependent and thus more prominent at higher doses. Un-
fortunately, such binding is lost during the washing steps
required in MMP activity assays and not recognizable in
Western blot analysis, and we are therefore unable to ad-
dress the relevance of such an effect.
CONCLUSIONS
Preoperative doxycycline therapy for 14 days resulted
in reduced aortic wall neutrophil content that is accompa-
nied by a selective suppression of neutrophil-derived pro-
teases and increased protein levels of the protease inhibitors
TIMP1 and cystatin C. Results from this study provide a
rationale for the evaluation of doxycycline as a therapeutic
means of inhibition of aneurysmal growth. Moreover, our
observations argue for a broader application for doxycy-
cline therapy in other pathologies involving neutrophil
infiltration and aneurysm formation, such as Kawasaki dis-
ease and Behçet disease,38,39 as well as nonvascular condi-
tions with prominent neutrophil involvement such as Sweet
syndrome40 and chronic obstructive pulmonary disease.41
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